ArticleClinical and translational radiation oncology2027
The value of community engagement in the ESTRO-EORTC OligoCare project: A quantification of the in-kind contributions.
Article in Clinical and translational radiation oncology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The OligoCare cohort constitutes the largest prospective dataset evaluating metastasis-directed radiotherapy in oligometastatic disease worldwide. Although the project received financial support for central coordination, no financial compensation for the operational involvement of the participating centres was available. This study quantified the in-kind professional contribution provided by the European radiation oncology community. Methods: In-kind professional contribution was defined as the sum of two components: time invested by clinical staff at enrolling centres for patient management, data collection, and follow-up; and time dedicated by Principal Investigators and Steering Committee members to protocol development, oversight, and coordination. A structured questionnaire was completed by the highest-accruing centres to estimate the time spent by each professional role. Median time requirements were combined with country-specific labour costs derived from OECD and EUROSTAT data to calculate the cost per patient at national level. A 20% overhead was applied to account for indirect activities. Results: As of August 2025, 3167 patients were enrolled. Questionnaire data from eleven centres (54% of total accrual) showed a median OligoCare-related workload of 218 min per patient (∼3.5 h). The cost per patient varied widely across Europe (79-322€), reflecting national differences in labour costs, resulting in a total in-kind contribution of 626,289€ from enrolling centres. Committee activities accounted for an additional 220,164€. Including overheads, the total in-kind contribution amounted to 1,015,744€. Conclusion: These findings demonstrate substantial in-kind contributions of the European Radiotherapy community, which were fundamental to the success of OligoCare. Quantifying these efforts supports fair recognition and the development of sustainable funding models for international research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.